Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
295.27
-5.10 (-1.70%)
At close: Jul 11, 2025, 4:00 PM
295.12
-0.15 (-0.05%)
After-hours: Jul 11, 2025, 7:50 PM EDT
Amgen Employees
Amgen had 28,000 employees as of December 31, 2024. The number of employees increased by 1,300 or 4.87% compared to the previous year.
Employees
28,000
Change (1Y)
1,300
Growth (1Y)
4.87%
Revenue / Employee
n/a
Profits / Employee
n/a
Market Cap
158.77B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 28,000 | 1,300 | 4.87% |
Dec 31, 2023 | 26,700 | 1,500 | 5.95% |
Dec 31, 2022 | 25,200 | 1,000 | 4.13% |
Dec 31, 2021 | 24,200 | -100 | -0.41% |
Dec 31, 2020 | 24,300 | 900 | 3.85% |
Dec 31, 2019 | 23,400 | 1,900 | 8.84% |
Dec 31, 2018 | 21,500 | 700 | 3.37% |
Dec 31, 2017 | 20,800 | 1,600 | 8.33% |
Dec 31, 2016 | 19,200 | 1,300 | 7.26% |
Dec 31, 2015 | 17,900 | 0 | - |
Dec 31, 2014 | 17,900 | -2,100 | -10.50% |
Dec 31, 2013 | 20,000 | 2,000 | 11.11% |
Dec 31, 2012 | 18,000 | 200 | 1.12% |
Dec 31, 2011 | 17,800 | 400 | 2.30% |
Dec 31, 2010 | 17,400 | 200 | 1.16% |
Dec 31, 2009 | 17,200 | 300 | 1.78% |
Dec 31, 2008 | 16,900 | -600 | -3.43% |
Dec 31, 2007 | 17,500 | -2,600 | -12.94% |
Dec 31, 2006 | 20,100 | 3,600 | 21.82% |
Dec 31, 2005 | 16,500 | 2,100 | 14.58% |
Dec 31, 2004 | 14,400 | 1,500 | 11.63% |
Dec 31, 2003 | 12,900 | 2,800 | 27.72% |
Dec 31, 2002 | 10,100 | 2,400 | 31.17% |
Dec 31, 2001 | 7,700 | 400 | 5.48% |
Dec 31, 2000 | 7,300 | 900 | 14.06% |
Dec 31, 1999 | 6,400 | 900 | 16.36% |
Dec 31, 1998 | 5,500 | 192 | 3.62% |
Dec 31, 1997 | 5,308 | 662 | 14.25% |
Dec 31, 1996 | 4,646 | 600 | 14.83% |
Dec 31, 1995 | 4,046 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AMGN News
- 2 days ago - Amgen: A Defensive Biotech With Yield And Optionality - Seeking Alpha
- 11 days ago - Amgen's gastric cancer drug meets late-stage trial goal - Reuters
- 11 days ago - AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER - PRNewsWire
- 17 days ago - Analyst Views Mixed As Amgen's Weight Loss/Diabetes Drug MariTide Shows Promise But Has Dose Issues - Benzinga
- 17 days ago - What's Happening With Amgen Stock? - Forbes
- 18 days ago - Amgen Inc. (AMGN) Presents at Special Call (IR Call) Conference Transcript - Seeking Alpha
- 18 days ago - Amgen Shares Fall on Weight-Loss Drug Tummy Troubles - Barrons
- 18 days ago - Low start dose of Amgen experimental weight-loss drug limits side effects - Reuters